Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 153 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: apixaban Clear all
Terminated Phase 1 Interventional

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

NCT01195727
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Orange, California • New Brunswick, New Jersey • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 4, 2026, 2:16 AM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 4, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional Results available

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

NCT04142658
View directory record Official record
Conditions
Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Failure
Interventions
Apixaban 5 MG, Apixaban 2.5 MG, Warfarin, On-X Aortic Mechanical Valve
Drug · Device
Lead sponsor
Artivion Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
62
States / cities
Tucson, Arizona • Little Rock, Arkansas • Loma Linda, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 4, 2026, 2:16 AM EDT
Active, not recruiting Not applicable Interventional

The PEERLESS II Study

NCT06055920
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 4, 2026, 2:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data

NCT04593030
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Warfarin, Apixaban
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
220,518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 4, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

NCT01758432
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PRT064445/Apixaban, Placebo/Apixaban, Placebo
Combination Product · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 4, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants

NCT02912234
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Clarithromycin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Sep 4, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Apixaban in Nephrotic Syndrome

NCT02599532
View directory record Official record
Conditions
Nephrotic Syndrome, Proteinuria
Interventions
apixaban
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 79 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 4, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers

NCT00914641
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban IR, Apixaban MR1, Apixaban MR2, Apixaban MR3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2009 · Synced Sep 4, 2026, 2:16 AM EDT
Not yet recruiting Phase 4 Interventional

Extended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease

NCT07713875
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Spine Metastasis
Interventions
Apixaban
Drug
Lead sponsor
James Bayley
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Pittburgh, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 4, 2026, 2:16 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Effectiveness of Patch-Based Screening for Pre-Symptomatic Atrial Fibrillation to Improve Patient Outcome

NCT06953778
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Zio XT® Patch
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
24,060 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2033
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 4, 2026, 2:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heparin Requirements in Patients Undergoing Atrial Fibrillation Ablation on Coumadin vs NOACs

NCT03520868
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Monitoring Anti Factor Xa level
Diagnostic Test
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 4, 2026, 2:16 AM EDT
Terminated Not applicable Interventional Results available

Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)

NCT05093504
View directory record Official record
Conditions
Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
Interventions
Sham comparator, DrugSorb-ATR system
Device
Lead sponsor
CytoSorbents, Inc
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
27
States / cities
Sacramento, California • Denver, Colorado • New Haven, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 4, 2026, 2:16 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Multi-site Study for Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants and Verification of Measurement Precision of Liquid Quality Controls With the Perosphere Technologies' PoC Coagulometer

NCT04868214
View directory record Official record
Conditions
Coagulation
Interventions
coagulation measurements
Device
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Danbury, Connecticut • Boynton Beach, Florida • Rockville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 4, 2026, 2:16 AM EDT
Completed No phase listed Observational

Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries

NCT02339818
View directory record Official record
Conditions
Stroke, Systemic Embolism, VTEt and VTEp
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 4, 2026, 2:16 AM EDT
Terminated Phase 3 Interventional Results available

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

NCT04498273
View directory record Official record
Conditions
COVID-19
Interventions
Apixaban 2.5 MG, Apixaban 5MG, Aspirin, Placebo
Drug
Lead sponsor
Frank C Sciurba
Other
Eligibility
40 Years to 80 Years
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
71
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Sep 4, 2026, 2:16 AM EDT
Withdrawn No phase listed Observational

Safety and Efficacy of Apixaban in Severe Renal Impairment

NCT03399305
View directory record Official record
Conditions
Renal Disease, End Stage, Anticoagulant-induced Bleeding
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 4, 2026, 2:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus

NCT03083782
View directory record Official record
Conditions
Venous Thromboembolism, Pharmacokinetics, Healthy
Interventions
Apixaban alone, Cyclosporine, Tacrolimus, Apixaban
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 4, 2026, 2:16 AM EDT
Completed No phase listed Observational Results available

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

NCT03026556
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran vs. Rivaroxaban, Dabigatran vs. Apixaban
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
42,534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 4, 2026, 2:16 AM EDT
Completed Not applicable Interventional Results available

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

NCT01999179
View directory record Official record
Conditions
Venous Thrombosis, Neoplasms
Interventions
Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 4, 2026, 2:16 AM EDT
Completed Phase 4 Interventional

Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation

NCT07699796
View directory record Official record
Conditions
Venous Thrombosis Deep (Limbs), Venous Insufficiency (Chronic)(Peripheral), Varicose Veins Leg, Venous Thrombosis
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Heart, Artery, and Vein Center of Fresno
Other
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 4, 2026, 2:16 AM EDT
Completed No phase listed Observational

The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants

NCT03535883
View directory record Official record
Conditions
Pleural Effusion, Thoracic Effusion
Interventions
Novel Oral Anti-Coagulants
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 4, 2026, 2:16 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Apixaban in Recent Acute Coronary Syndrome

NCT00313300
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
30
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Sep 4, 2026, 2:16 AM EDT
Completed Not applicable Interventional

Comparison of Apixaban Versus Enoxaparin

NCT06243510
View directory record Official record
Conditions
Bladder Cancer
Interventions
apixaban, enoxaparin
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 4, 2026, 2:16 AM EDT